Oxford BioMedica Current Ratio 2021-2020 | OXBDF

Oxford BioMedica current ratio from 2021 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Oxford BioMedica Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2020-12-31 $0.14B $0.07B 2.06
2020-06-30 $0.11B $0.04B 2.89
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.660B $0.113B
Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86